IP Library › Granted Patent US 12,735,483
Granted Patent B2
US 12,735,483 · App. 18/318,776 · Granted Sep 15, 2026

Anti-TIGIT antibodies and methods of use

Inventors: Min-Yuan Chou (Taipei City, TW); Li-Tsen Lin (New Taipei City, TW); Chung-Yuan Sun (Hsinchu County, TW); Ya-Ping Lai (Hsinchu City, TW); Chin-Pen Lai (Hsinchu County, TW); Ssu-Yuan Wu (Hsinchu City, TW); Mei-Wei Lin (Hsinchu County, TW)
Assignee: Industrial Technology Research Institute
C07K16/2803A61P35/00A61K45/06C07K2317/565C07K2317/567
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,483
App. No.
18/318,776
Granted
Sep 15, 2026
Kind
B2
Abstract

Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Claims (13)

1 . An isolated antibody or antigen-binding fragment that specifically binds to human T cell immunoglobulin and ITIM domain (TIGIT), wherein the antibody or antigen-binding fragment comprises:

three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3);

three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 23 (LCDR3);

a heavy chain variable region that is at least 91% identical to an amino acid sequence of SEQ ID NO: 39; and

a light chain variable region that is at least 91% identical to an amino acid sequence of SEQ ID NO: 40.

2 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 92% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 92% identical to an amino acid sequence of SEQ ID NO: 40.

3 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 93% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 93% identical to an amino acid sequence of SEQ ID NO: 40.

4 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 94% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 94% identical to an amino acid sequence of SEQ ID NO: 40.

5 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 95% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 95% identical to an amino acid sequence of SEQ ID NO: 40.

6 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 96% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 96% identical to an amino acid sequence of SEQ ID NO: 40.

7 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 97% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 97% identical to an amino acid sequence of SEQ ID NO: 40.

8 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 98% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 98% identical to an amino acid sequence of SEQ ID NO: 40.

9 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that is at least 99% identical to an amino acid sequence of SEQ ID NO: 39, and a light chain variable region that is at least 99% identical to an amino acid sequence of SEQ ID NO: 40.

Continuity (3)
Continuation 16948563 · Sep 23, 2020
Provisional Application 62904752 · Sep 24, 2019
Related Publication 20230416362A1 · Dec 28, 2023
References Cited (37)
US 9334331B2 · Igawa et al. · 2016 [cited by applicant]
US 9713641B2 · Hicklin et al. · 2017 [cited by applicant]
US 10017572B2 · Grogan et al. · 2018 [cited by applicant]
US 10047158B2 · Grogan et al. · 2018 [cited by applicant]
US 10112997B2 · Gurney et al. · 2018 [cited by applicant]
US 10189902B2 · Maurer et al. · 2019 [cited by applicant]
US 10213505B2 · White et al. · 2019 [cited by applicant]
US 10329349B2 · Cooper et al. · 2019 [cited by applicant]
US 11667709B2 · Chou · 2023 [cited by examiner]
US 20180066055A1 · Williams et al. · 2018 [cited by applicant]
US 20210252059A1 · Pu et al. · 2021 [cited by applicant]
TW 201915026 · 2019 [cited by applicant]
WO WO2009126688A2 · 2009 [cited by applicant]
WO WO2014089169A2 · 2014 [cited by applicant]
WO WO2015009856A2 · 2015 [cited by applicant]
WO WO2016028656A1 · 2016 [cited by applicant]
WO WO2016106302A1 · 2016 [cited by applicant]
WO WO2018102536A1 · 2018 [cited by applicant]
WO WO2018204363A1 · 2018 [cited by applicant]
WO WO2019023504A1 · 2019 [cited by applicant]
WO WO2019154415A1 · 2019 [cited by applicant]
Communication Pursuant to Article 94(3) EPC in counterpart European Patent Application No. 20197922.6 dated Feb. 5, 2024, (5 pages). [cited by applicant]
Chauvin, Joe-Marc et al., “TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients”, The Journal of Clinical Investigation, vol. 125, No. 5, (2015), pp. 2046-2058. [cited by applicant]
Chew, G. M. et al., “TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection”, PLOS Pathogens, (Jan. 7, 2016), pp. 1-28. [cited by applicant]
Edwards, B. M. et al., “The Remarkable Flexibility of the Human Antibody Repoertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS”, Journal of Mol. Biology, vol. 334, (2003), pp. 103-11… [cited by applicant]
Extended European Search Report in counterpart European Application No. 20197922.6, filed Sep. 23, 2020, mailed Feb. 12, 2021, 12 pages. [cited by applicant]
Fan, Chia-Yu et al., “De novo protein sequencing, humanization and in vitro effects of an antihuman CD34 mouse monoclonal antibody”, Biochemistry and Biophysics Reports, vol. 9, (2017), pp. 51-60. [cited by applicant]
Hummer, A. M et al., “Advances in Computational Structure-Based Antibody Design”, Current Opinion in Structural Biology, vol. 74:102379, (2022), 7 pages. [cited by applicant]
Hung, A. L. et al., “IT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM”, Oncoimmunology, vol. 7, No. 8, (2018), 13 pages. [cited by applicant]
Johnston, R. J. et al., “The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function”, Cancer Cell, vol. 26, (2014), pp. 923-937. [cited by applicant]
Lazar, G. A. et al., “Engineered antibody Fc variants with enhanced effector function”, PNAS, vol. 103, No. 11, (2006), pp. 4005-4010. [cited by applicant]
Li, D. et al., “Phage Display Screening of TIGIT-specific antibody for antitumor immunotherapy”, Bioscience, Biotechnology, and Biochemistry, vol. 83, No. 9, (2019), pp. 1683-1696. [cited by applicant]
Liu, H. et al., “In vitro and in vivo modifications of recombinant and human IgG antibodies”, mAbs, vol. 6, No. 5, (Sep./Oct. 2014), pp. 1145-1154. [cited by applicant]
Lozano, E. et al., “The TIGIT/CD226 Axis Regulates Human T Cell Function”, J. Immunol., vol. 188, (2012), pp. 3869-3875. [cited by applicant]
Srivastava, M. K. et al., “Anti-TIGIT induces T cell-mediated anti-tumor immune responses and combines with immune checkpoint inhibitors to enhance strong and long term anti-tumor immunity”, OncoMed Pharmaceuticals, Inc… [cited by applicant]
Stengel, K. F. et al., “Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering”, PNAS, vol. 109, No. 14, (2012), p… [cited by applicant]
Yu, X. et al., “The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells”, Nature Immunology, vol. 10, No. 1, (2009), pp. 48-57. [cited by applicant]